ArticleOncotarget2011
TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.
Article in Oncotarget, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Limited Proteolysis as a Regulator of Lymphatic Vessel Function and Architecture.International journal of molecular sciences · 2025Review
- StarD13: a potential star target for tumor therapeutics.Human cell · 2020Review
- Recent progress in mapping the emerging landscape of the small-cell lung cancer genome.Experimental & molecular medicine · 2019Review
- Inhibition of DNA‑PK activity sensitizes A549 cells to X‑ray irradiation by inducing the ATM‑dependent DNA damage response.Molecular medicine reports · 2018Article
- DLC2 inhibits development of glioma through regulating the expression ratio of TAp73α/TAp73β.American journal of cancer research · 2018Article
- Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.Oncotarget · 2016Article
- Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.Oncotarget · 2014Article
- GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation.Cell cycle (Georgetown, Tex.) · 2013Article
- miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2.Journal of cancer research and clinical oncology · 2013Article
- Mechanisms, function and clinical applications of DNp73.Cell cycle (Georgetown, Tex.) · 2013Review
- Article
- Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure.Cell cycle (Georgetown, Tex.) · 2013Article
- TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics.Oncotarget · 2013Article
- p63 the guardian of human reproduction.Cell cycle (Georgetown, Tex.) · 2012Review
- Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Oncotarget · 2012Review
- Tissue-specific expression of p73 C-terminal isoforms in mice.Cell cycle (Georgetown, Tex.) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspase-2 is ubiquitously expressed and the most evolutionarily conserved mammalian caspase. It can be activated by a range of death stimuli prior to Bax activation and the occurrence of apoptotic mitochondrial dysfunctions. Caspase-2 has also been reported to exert tumour suppressor function in vivo. The full length TAp73alpha isoform is found up-regulated in various tumour types, and is reported in a cell-type specific manner to repress drug-induced apoptosis. Here, we report that TAp73alpha represses caspase-2 enzymatic activity and by this means reduce caspase-2 induced Bax activation, loss of mitochondrial transmembrane potential and resulting apoptosis. The inhibitory effect on caspase-2 requires the presence of the DNA binding domain and SAM domain region of TAp73alpha. In conclusion, the ability of TAp73alpha to act as an inhibitor of caspase-2-induced cell death together with its up-regulation in certain tumour types strengthen the potential oncogenic activities for this protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.